A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN).

被引：0
|
作者：
Clump, David Anthony
Zandberg, Dan Paul
Skinner, Heath Devin
Ohr, James
Fenton, Moon Jung
Normolle, Daniel Paul
Beitler, Jonathan Jay
Bauman, Julie E.
Ferris, Robert L.
机构：
[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh Canc Inst, Seven Fields, PA USA
[3] Univ Pittsburgh, Pittsburgh, PA USA
[4] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Univ Arizona Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6007
引用
收藏
页数：1
相关论文
共 45 条
  • [31] Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial
    Andrea Guttilla
    Roberto Bortolus
    Gianluca Giannarini
    Pirus Ghadjar
    Fabio Zattoni
    Michele Gnech
    Vito Palumbo
    Francesca Valent
    Antonio Garbeglio
    Filiberto Zattoni
    Radiation Oncology, 9
  • [32] Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial
    Guttilla, Andrea
    Bortolus, Roberto
    Giannarini, Gianluca
    Ghadjar, Pirus
    Zattoni, Fabio
    Gnech, Michele
    Palumbo, Vito
    Valent, Francesca
    Garbeglio, Antonio
    Zattoni, Filiberto
    RADIATION ONCOLOGY, 2014, 9
  • [33] 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
    Bourhis, J.
    Sun, X.
    Le Tourneau, C.
    Pointreau, Y.
    Sire, C.
    Kaminsky-Forrett, M-C.
    Coutte, A.
    Alfonsi, M.
    Boisselier, P.
    Martin, L.
    Delord, J-P.
    Clatot, F.
    Biau, J.
    Rolland, F.
    Gollmer, K.
    Szyldergemajn, S. A.
    Even, C.
    Tao, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1168 - S1168
  • [34] NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Harris, Jonathan
    Uppaluri, Ravindra
    Yao, Min
    Ferris, Robert L.
    Chen, Josephine
    Jordan, Richard C.
    Joshi, Nikhil Purushottam
    Jujjuvaparu, Srinivas
    Blakaj, Dukagjin
    Razaq, Mohammad
    Sheqwara, Jawad
    Mell, Loren K.
    Sen, Neilayan
    Clump, David Anthony
    Garg, Madhur
    Yilmaz, Emrullah
    Quynh-Thu Le
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).
    Waldron, John N.
    Parulekar, Wendy
    O'Sullivan, Brian
    Chen, Bingshu E.
    Montenegro, Alexander
    Nabid, Abdenour
    Winquist, Eric
    Wright, Jim R.
    Hay, John
    Ringash, Jolie
    Martino, Rosemary
    Johnson, Ana
    Liu, Geoffrey
    Breen, Stephen
    Gilbert, Ralph William
    Shenouda, George
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
    Wong, Deborah J.
    Fayette, Jerome
    Teixeira, Maria
    Prabhash, Kumar
    Mesia, Ricard
    Kawecki, Andrzej
    Dechaphunkul, Arunee
    Dinis, Jose
    Guo, Ye
    Masuda, Muneyuki
    Hsieh, Ching-Yun
    Ghi, Maria Grazia
    Sette, Claudia Vaz de Melo
    Jiang, Tao
    Yan, Yibing
    Kaul, Monika
    Jagtiani, Ritika
    Matheny, Christina
    Cuchelkar, Vaikunth
    Haddad, Robert
    CANCER RESEARCH, 2024, 84 (07)
  • [37] heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
    Kuemmel, Sherko
    Harper-Wynne, Catherine
    Park, Yeon Hee
    Franke, Fabio
    de Laurentiis, Michelino
    Schumacher-Wulf, Eva
    Eiger, Daniel
    Heeson, Sarah
    Cardona, Andres
    Ozyilkan, Ozgur
    Morales-Vasquez, Flavia
    Metcalfe, Ciara
    Hafner, Marc
    Restuccia, Eleonora
    O'Shaughnessy, Joyce
    BMC CANCER, 2024, 24 (01)
  • [38] MULTIMODAL TREATMENT FOR HIGH-RISK PROSTATE CANCER WITH HIGH-DOSE INTENSITY-MODULATED RADIATION THERAPY, CONCURRENT INTENSIFIED-DOSE DOCETAXEL AND LONG-TERM ANDROGEN DEPRIVATION THERAPY AFTER RADICAL PROSTATECTOMY AND LYMPHADENECTOMY: RESULTS OF A PROSPECTIVE PHASE II TRIAL.
    Zattoni, Fabio
    Bortolus, Roberto
    Morlacco, Alessandro
    Arcicasa, Mauro
    Matrone, Fabio
    Zattoni, Filiberto
    JOURNAL OF UROLOGY, 2017, 197 (04): : E718 - E719
  • [39] Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
    Yeon Joo Kim
    Hanjong Ahn
    Choung-Soo Kim
    Jae-Lyun Lee
    Young Seok Kim
    Trials, 19
  • [40] Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
    Kim, Yeon Joo
    Ahn, Hanjong
    Kim, Choung-Soo
    Lee, Jae-Lyun
    Kim, Young Seok
    TRIALS, 2018, 19
12345